Indutrade AB (publ)

Welcome to the Indutrade Q2 presentation for 2025. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Bo Anvik and CFO Patrick Johnson. Please go ahead.

Welcome and good morning on our behalf as well. As usual, let's begin with the overall highlights. starting with the demand situation the order intake was stable organically unchanged from last year despite fewer working days and the uncertain market situation so underlying it was stronger than last year around half of the companies had organic order intake growth with good demand from customers within the energy sector Demand within medical technology and pharmaceuticals was aggregated on a high and stable level. Net sales decreased 4% in total, organically also minus 4%. And I will soon comment more on this. The EBITDA margin came in at 13.7%. We continued to reduce inventory during the quarter. Four acquisitions completed so far in 2025. We have prolonged some of the acquisition processes due to the general market uncertainty, but the pipeline now is very strong. Looking more specifically at the order intake and sales trends, demand was underlying stronger than last year, considering the number of working days during the quarter. We had a positive book-to-bill also this quarter with orders being 2% higher than sales. It's the second quarter in a row with a positive book-to-bill. There were continued variation between companies, segments and countries with the strongest growth in the energy sector. The demand within medical and pharmaceuticals was high and stable. Demand within infrastructure and construction, general engineering and the process industry was weaker. In terms of sales, we declined 4% during the quarter as an effect of currency headwinds and a minus 4% organic decline, while acquisitions contributed positively. The organic sales development is primarily explained by the lower order backlog coming into the quarter, as well as strong references, especially for business area, life science and fewer working days. I think visually you can actually see at the net sales bar diagram that quarter two 2024 stands out with an all time high sales of 8.5 billion SEK. I think it's also good for you to understand that if we exclude the two companies with the highest sales to Novo Nordisk, that has a 2% impact on sales this quarter. So instead of minus four, it will be minus two. And if we exclude the working day effect, it's also around 2%. With those two sort of adjustments, it's a flat sales situation. Basically, perhaps giving you a better understanding of the overall situation within the group. Moving into sales per geographical market, sales to Sweden was overall flat with good demand within, for example, the energy sector and infrastructure related business. while it was lower in medical technology and pharmaceuticals, mainly due to challenging references. Sales in Denmark was down due to strong sales to Novo Nordisk the same period last year. Also Finland and Norway was aggregated down year over year. For rest of Europe, sales development was stable in the Benelux, UK, Ireland and Switzerland and Austria. sales growth was strong for single use products but lower for infrastructure construction related business and general engineering especially in germany sales to north america and asia is slightly volatile and the development can fluctuate with single projects in north america we had a strong development within valves for power generation while some of the companies in the business area technology and system solutions had a weaker development on the back of hesitation from US customers due to the tariff situation. All in all, it was flat from last year and down in Asia. EBITDA decreased 11% in total to 1.1 billion SEK, corresponding to an EBITDA margin of 13.7%. An improvement sequentially from from 13.3% in Q1, but lower than 14.8% last year. The organic sales development of minus 4% is of course the main driver of the underlying EBITDA margin decline versus last year. The gross margin was stable and high at 35.3%, basically in line with last year. We also start to see some effects from our company's efforts in terms of adapting costs to the situation prevailing in their markets with organic expenses being flat compared to the same period last year and also lower than the first quarter. This is a positive development effort and the work will obviously continue also into Q3 and Q4. If we then comment on the net sales per business area, as mentioned, some headwinds in terms of fewer working days, strong references and the lower order book coming into the quarter, resulting in a negative organic sales development for all business areas. The main explanation for the organic sales drop in business area life science is that they had very strong sales during the same period last year connected to diabetes related products in the Nordics. and production equipment to Novo Nordisk in Denmark. We saw continued good development within the single use area during the quarter, and over half of the companies in the business area had organic growth in both sales and orders. If we do the same exercise for business area life science and exclude the two companies with the highest sales to Novo Nordisk in the quarter, the organic sales would go from minus 4% to plus 4% for the business area. So big impact from very few companies, but also good to know that those companies are two very good companies and you will see that they will have positive impact also order intake wise and sales wise going forward. Process energy and water was impacted negatively by weak development within the Finnish process industry, and the weak general business climate continued to impact infrastructure and construction, industrial and engineering, and technology and system solutions. As mentioned, for technology and system solutions, it was primarily sales to North America and Asia that was weak, I can also mention that we have appointed a new head of business area, technology and system solutions, Mr. Peter Laveson, an external recruit who will start towards the end of August with a very relevant background. If we then turn to EBITDA margin by business area, As mentioned, we had stable high gross margin and positive expense development. However, all business areas had a declining EBITDA margin in the quarter. In addition to the organic sales development, slightly higher expenses had a negative effect in industrial and engineering and life science. Infrastructure and construction had a slightly lower gross margin, but was impacted positively by acquisitions, divestments and restructuring activities. Processed energy and water had the weakest margin development compared to the same period last year. However, they had the best improvement from quarter one. technology and system solutions was impacted negatively by some one-offs connected to, for instance, layoffs in addition to the organic sales decline. Sequentially, the beta margin improved versus Q1 in all business areas except for technology and system solutions. If we then turn to acquisitions, so far this year, The acquisition pace has been somewhat lower with four acquisitions completed, adding approximately 425 million second annual revenues to the group. Due to the general market uncertainty that also intensified in April with the tariff announcements from the US, we decided to prolong some of our acquisition processes. We do, however, remain very opportunity oriented and are looking for a wide range of companies in many different geographies and segments. The pipeline is now very strong and we are working on several projects in different stages. So we are confident that the second half of this year will be successful in terms of acquisitions. Looking at the longer trend, more importantly, we are stepwise increasing the number of acquisitions per year, as can be seen in the yellow line to the left. Although number of acquisitions per year can be a bit volatile. Looking at the bridge effects from acquisitions over the last 12 months, we have added over 100 million SEC to the Groups EBITDA in 2025. Furthermore, we can also see that the acquisitions are margin accretive with an accumulated EBITDA margin of 17.3% for the quarter and also over 70% on a rolling 12-month basis. Then I hand over the word to Patrick to comment more on the financials.

Yes, hello everyone and thanks Bo. Looking at the financials in more detail. Total growth for orders and sales in the quarter was plus minus zero and minus four respectively. Year-to-date orders have grown 3% and sales is in line with last year. Book-to-bill above one in the quarter and also for the first half year. So that's encouraging and good. In quarter two, we continue to have stable high gross margin development, 35.3 versus 35.4 last year. And year to date, we are slightly ahead of last year. The beta decreased with 11% in the quarter and is minus three year to date. Quarter two EBITDA margin was 13.7 compared to 14.8 last year and as Bo commented a slight improvement versus Q1 when we had 13.3 excluding one offs. Finance net decreased 17% in the quarter and 8% year to date mainly because of the lower interest rates. Costs are down 10% in the quarter and down 4% year to date, basically in line with the result movement. So underlying tax rate is therefore in line with last year at around 23%. Earnings per share decreased with 12% in the quarter and 4% year to date. And I will show and talk around the graphical trend on the following slides. Return on capital employed is at 19%, which is slightly below last year and also slightly below our target. Operational cash flow was down in the quarter and I will also elaborate a bit further on that on the coming slides. Net debt EBDA end of the quarter is at 1.5 versus 1.7 last year. so let let's look at a few more details on starting them with with cash flow cash flow as i said then is down during the quarter and the drivers here are the lower result of course but also less favorable working capital movements We've had two years of very strong cash flows, as you can see from the slide, supported by large working capital releases, mainly connected to inventory. We have, of course, an ambition to improve the capital efficiency further, but inventory levels are now more normalized, I would say, and further working capital releases will be sort of marginal. During the quarter, we also had less favorable cash flow movements in the more project-like businesses we have with the less advances and more project build-ups, which also impacts the cash flow somewhat. However, if you look specifically at the inventories, they declined organically slightly since last quarter, and the total organic working capital is also lower than last year. Cash conversion is continued on a good high level, right now trending on a rolling four-quarter basis at 131% compared to net profit less capex. As I said earlier, the working capital efficiency is the focus area for us going forward. And despite the lower organic sales, the working capital ratio in relation to sales has improved since last year. Moving on to looking at earnings per share, that amounted to 1.71 SEK in the quarter compared to 2 SEK last year. And decline is of course mainly an effect of the lower operational result. The lower interest costs, they compensate slightly. The interest net has otherwise been a headwind if you look at the more longer development the last two years, 23 and 24. But they have come down now somewhat to a more, call it a normalized level. Looking at the longer perspective and the average growth in the three and five year rolling, four quarter earnings per share, they are at 4% and 12% respectively. And then ending with the financial position that is still very strong. The interest bearing net debt decreased versus last year from 9.5 billion SEK to 8.4. Mainly as a result of strong cash flows the last year but also then a lower acquisition pace. Net debt however increased seasonally compared to the first quarter due to the dividend payout. If you look at the net debt ratios, they are stable and low from a longer historical perspective. Net debt to equity ratio was 52% compared to 63% last year. and the net debt ebda ratio was 1.5 as i said earlier than compared to 1.7 last year and if you exclude earn out liabilities the net debt ebda ratio is 1.4 compared to 1.6 last year So to conclude, the financial position is strong and that of course creates good conditions for continued value creative acquisitions and also organic growth investments. By that I leave over back to Bo.